Development and validation of a primary sclerosing cholangitis–specific patient-reported outcomes instrument: The PSC PRO

Hepatology

Volumn 68, Issue 1, 2018, Pages 155-165

  Younossi, Zobair M ^a,b   Afendy, Arian ^c   Stepanova, Maria ^c   Racila, Andrei ^c   Nader, Fatema ^c   Gomel, Rachel ^d   Safer, Ricky ^d   Lenderking, William R ^e   Skalicky, Anne ^e   Kleinman, Leah ^e   Myers, Robert P ^f   Subramanian, G Mani ^f   McHutchison, John G ^f   Levy, Cynthia ^g   Bowlus, Christopher L ^h   Kowdley, Kris ⁱ   Muir, Andrew J ^j  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

^c Center for Outcomes Research in Liver Diseases   (United States)

^d PSC Partners Seeking a Cure   (United States)

^e EVIDERA   (United States)

^f GILEAD SCIENCES   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ SWEDISH MEDICAL CENTER   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 D ITCH SCALE; ADULT; ARTICLE; CHRONIC LIVER DISEASE QUESTIONNAIRE; CONSTRUCT VALIDITY; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DISCRIMINANT VALIDITY; EXTERNAL VALIDITY; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; INTERNAL CONSISTENCY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PATIENT-REPORTED OUTCOME; PRIMARY BILIARY CHOLANGITIS 40; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SHORT FORM 36; TEST RETEST RELIABILITY; MIDDLE AGED; REPRODUCIBILITY; SCLEROSING CHOLANGITIS; VALIDATION STUDY;

ADULT; CHOLANGITIS, SCLEROSING; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; REPRODUCIBILITY OF RESULTS;

EID: 85045902899     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.29664     Document Type: Article

References (22)

1. Boonstra K, Weersma RK, van Erpecum KJ, Rauws EA, Spanier BW, Poen AC, van Nieuwkerk KM; EpiPSCPBC Study Group. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013;58:2045-2055.
2. Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology 2013;145:521-536.
3. Worthington J, Chapman R. Primary sclerosing cholangitis. Orphanet J Rare Dis 2006;1:41.
4. Schulze K, Weismüller TJ, Bubenheim M, Huebener P, Zenouzi R, Lenzen H, et al.; German PSC Study Group. Criteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with Primary Sclerosing Cholangitis. PLoS One 2015;10:e0140525.
5. Haapamäki J, Tenca A, Sintonen H, Barner-Rasmussen N, Färkkilä MA. Health-related quality of life among patients with primary sclerosing cholangitis. Liver Int 2015;35:2194-2201.
6. Cheung AC, Patel H, Meza-Cardona J, Cino M, Sockalingam S, Hirschfield GM. Factors that influence health-related quality of life in patients with primary sclerosing cholangitis. Dig Dis Sci 2016;61:1692-1699.
7. National Quality Forum. Patient Reported Outcome. https://www.qualityforum.org/Projects/n-r/Patient-Reported_Outcomes/Patient-Reported_Outcomes.aspx. Accessed on July 31, 2017.
8. van der Plas SM, Hansen BE, de Boer JB, Stijnen T, Passchier J, de Man RA, Schalm SW. Generic and disease-specific health related quality of life of liver patients with various aetiologies: a survey. Qual Life Res 2007;16:375-388.
9. Friese S, Ringmayr TG. ATLAS.ti 7 User Manual, 2013. http://atlasti.com/wp-content/../05/atlasti_v7_manual_201312.pdf?../atlasti..201312. Accessed July 31, 2017.
10. Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med 2001;33:350-357.
11. Younossi Z M, Guyatt G, Kiwi M, N Boparai, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999;45:295-300.
12. Jacoby A, Rannard A, Buck D, Bhala N, Newton JL, James W, Jones D. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. Gut 2005;54:1622-1629.
13. Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D Itch Scale: a new measure of pruritus. Br J Dermatol 2010;162:587-593.
14. Shrout PE1, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull 1979;86:420-428.
15. Younossi ZM, Stepanova M, Henry L. Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C. Value Health 2016;19:544-551.
16. Mohsen Tavakol M, Dennick R. Making sense of Cronbach's alpha. Int J Med Educ 2011;2:53-55.
17. Sano H, Nakazawa T, Ando T, Hayashi K, Naitoh I, Okumura F, et al. Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci 2011;18:154-161.
18. Ponsioen CY. Diagnosis, differential diagnosis, and epidemiology of primary sclerosing cholangitis. Dig Dis 2015;33(Suppl 2):134-139.
19. Busner J, Targum SD. The Clinical Global Impressions Scale—applying a research tool in clinical practice. Psychiatry 2007;4:28-37.
20. Bowlus CL, Li CS, Karlsen TH, Lie BA, Selmi C. Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations. Liver Transpl 2010;16:1324-1330.
21. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012;56:1181-1188.
22. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994;106:287-296.